CollinBlakelyMDPh.D.
Oncology • San Francisco, CAHematologic Oncology, Thoracic Cancer
Clinical Instructor, Internal Medicine, UCSF School of Medicine
Dr. Blakely is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave
San Francisco, CA 94143Phone+1 415-885-7276Fax+1 415-353-9615
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2009 - 2011
University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2009
Perelman School of Medicine at the University of PennsylvaniaClass of 2007
Certifications & Licensure
CA State Medical License 2009 - 2026
PA State Medical License 2007 - 2009- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rociletinib (CO-1686) USA Expanded Access Program
- Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2017 Sep 09
- Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery Start of enrollment: 2018 Jul 31
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsPERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors.Sanju Sinha, Rahulsimham Vegesna, Sumit Mukherjee, Ashwin V Kammula, Saugato Rahman Dhruba
Nature Cancer. 2024-06-01 - 375 citationsEvolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M. Blakely, Thomas B.K. Watkins, Wei Wu, Beatrice Gini, Jacob J. Chabon
Nature Genetics. 2017-11-06 - 206 citationsRAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.Gorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos, Asmin Tulpule, Saurabh Asthana
Nature Medicine. 2015-09-01
Journal Articles
- Aurora Kinase A Drives the Evolution of Resistance to Third-Generation EGFR Inhibitors in Lung CancerVictoria E Wang, Collin M Blakely, Trever G Bivona, Andrei Goga, Nature
- Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationJulia K Rotow, Trever G Bivona, Collin M Blakely, Clinical Lung Cancer
Authored Content
- Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationNovember 2018
Press Mentions
Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021
Deadly Lung Cancers Are Driven by Multiple Genetic ChangesNovember 6th, 2017
Deadly Lung Cancers Are Driven by Multiple Genetic ChangesNovember 6th, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
